Four epidemics (SARS in 2003, pandemic influenza in 2009, Ebola in 2014, and the COVID-19 pandemic in 2020) have revealed strengths and weaknesses in our nation's ability to coordinate a comprehensive response.

The Duke Human Vaccine Institute's Pandemic Preparedness programs seek to build upon our world-class expertise in pandemic preparedness training, virology, immunology and CGMP manufacturing to strengthen our national response to future pandemic emergencies. We are taking a holistic approach to include pandemic preparedness training to improve and provide occupational training to those who may be exposed to infectious diseases and rapid development of pathogen-specific countermeasures to be deployed in a pandemic emergency. The DHVI Pandemic Preparedness programs include the Duke DARPA Pandemic Prevent Platform (P3) program and the Duke Infectious Diseases Response Training (DIDRT) .

In response to the anthrax attacks of 2001, the NIAID/NIH funded construction of 12 Regional Biocontainment Laboratories (RBLs) with two mandates:

  • Provide state-of-the-art containment space to support research on drugs, diagnostics and vaccines against biological threats and emerging infections
  • Support local and national responses to infectious disease emergencies.

RBLs were strategically constructed at major academic medical centers to create a broad research and response-training network. The Duke RBL facility in the DHVI is the home of the two Pandemic Preparedness programs: DIDRT and P3.

Related News

Our Best Shot - DHVI Documentary

The Duke Human Vaccine Institute (DHVI) was featured in a WRAL-TV documentary about the coronavirus pandemic and DHVI’s efforts to combat it. 

The Duke CIVICs investigators featured in the documentary include Dr. Tom Denny, Dr. Tony Moody, and Dr. Greg Sempowski. Learn more about DHVI and its efforts to develop a coronavirus vaccine. 

VIDEO: What is considered good vaccine efficacy?

DHVI Investigator and director of the Duke CIVICs Vaccine Center (DCVC), Dr. Tony Moody answers questions about effectiveness of the Moderna, Pfizer and Johnson & Johnson vaccines. Dr. Moody is a Professor of Pediatrics at Duke and an experienced clinician in Pediatric Infectious Diseases.

School of Medicine Expands to RTP, January 2021

The Duke University School of Medicine is expanding into a newly-leased research center in the Research Triangle Park (RTP). The 273,000 square foot facility in the Parmer RTP research and development campus, formerly home to pharmaceutical maker GlaxoSmithKline, is currently being renovated to accommodate School of Medicine faculty, staff and labs as soon as January 2021.